🇺🇸 FDA

Intelligence · Patent portfolio

Takeda Patents

Full USPTO pharma patent portfolio for Takeda — grant dates, expiration, and drug cross-links.

Patents
1,436
Expiring ≤24m
81

Quick answer

Takeda has 1,436 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 81 expire within 24 months — use filters for patent-cliff planning.

Page 13 of 30

  1. US 9221836

    Heterocyclic compound and use thereof

    Expires Mon Dec 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 9212149

    Substituted 2-amidoquinazol-4-ones as matrix metalloproteinase-13 inhibitors

    Expires Mon Dec 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 9211323

    Compositions and methods for administration of vaccines against dengue virus

    Expires Mon Dec 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9212147

    Dihydroxy aromatic heterocyclic compound

    Expires Mon Dec 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9205044

    Aqueous pharmaceutical preparation comprising roflumilast

    Expires Mon Dec 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9200051

    Peptide compound

    Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9199963

    Heterocyclic compound

    Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9193709

    1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases

    Expires Mon Nov 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9187497

    Substituted pyrido[3,2-e]pyrrolo[1,2-a]pyrazines as inhibitors of poly(ADP-ribose)polymerase (PARP)

    Expires Mon Nov 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9187453

    Heterocyclic compound

    Expires Mon Nov 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9186411

    Pharmaceutical composition

    Expires Mon Nov 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9181255

    Fused heteroaromatic pyrrolidinones as SYK inhibitors

    Expires Mon Nov 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9180122

    5- or 6-substituted 3-hydroxy-2 (1 H)-pyridinones as D-amino acid oxidase (DAAO) inhibitors in therapy of diseases such as schizophrenia, cognitive disorder and pain

    Expires Mon Nov 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9181186

    Aromatic ring compound

    Expires Mon Nov 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9181249

    Substituted pyrido[3,4-b]pyrazines as GPR6 modulators

    Expires Mon Nov 05 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9175037

    Neuromedin U derivative

    Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9173849

    Solid pharmaceutical composition

    Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9169238

    Solid pharmaceutical composition

    Expires Mon Oct 22 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9156829

    Cycloalkyl and heterocycloalkyl compounds as orexin receptor antagonists

    Expires Mon Oct 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9156837

    Heterocyclic compound

    Expires Mon Oct 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9157069

    Method of producing pancreatic hormone-producing cells

    Expires Mon Oct 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9150588

    Substituted pyridazin-4(1H)-ones as phosphodiesterase 10A inhibitors

    Expires Mon Oct 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9150591

    Heterocyclic compound and use thereof

    Expires Mon Oct 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9149437

    Method for treatment of solid pharmaceutical preparation prior to printing and solid pharmaceutical preparation subjected to treatment prior to printing

    Expires Mon Oct 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9149479

    Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors

    Expires Mon Oct 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9145389

    Benzimidazole compound crystal

    Expires Mon Sep 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9139598

    Glucokinase activators

    Expires Mon Sep 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9133129

    Bicyclic compound

    Expires Mon Sep 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9120777

    Heterocyclic compound

    Expires Mon Aug 27 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9120776

    Condensed heterocyclic compound

    Expires Mon Aug 27 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9115136

    Fused ring compound and use thereof

    Expires Mon Aug 20 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9115139

    Pyrazinooxazepine derivatives

    Expires Mon Aug 20 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9108970

    Fused heteroaromatic pyrrolidinones

    Expires Mon Aug 13 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9107912

    Methods for concomitant treatment of theophylline and febuxostat

    Expires Mon Aug 13 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9101660

    Solid preparation

    Expires Mon Aug 06 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 9102744

    Conjugated anti-CD38 antibodies

    Expires Mon Aug 06 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 9102666

    Methods and drug products for treating Alzheimer's disease

    Expires Mon Aug 06 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 9101565

    Dissolution stability of calcium carbonate tablets

    Expires Mon Aug 06 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 9090586

    Heterocyclic compound

    Expires Mon Jul 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 9090597

    Pyrazolone derivatives as PDE4 inhibitors

    Expires Mon Jul 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 9085578

    Heterocyclic compound

    Expires Mon Jul 16 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 9079907

    Fused heterocyclic compound and use thereof

    Expires Mon Jul 09 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 9073918

    Pyrazolo[4,3-b]pyridine-7-amine inhibitors of ALK5

    Expires Mon Jul 02 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 9073864

    Aromatic ring compound

    Expires Mon Jul 02 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 9066936

    Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent

    Expires Mon Jun 25 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 9060941

    Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative

    Expires Mon Jun 18 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 9056873

    Substituted 6-aza-isoindolin-1-one derivatives

    Expires Mon Jun 11 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 9045436

    Heterocyclic compound and use thereof

    Expires Mon May 28 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Takeda have?

1,436 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Takeda patents expire?

81 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.